Last checked at 7 Feb 2017 12:32
7 February 2017 | AIM: RENE |
ReNeuron Group plc
("ReNeuron" or the "Company")
Director Share Purchase
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, was informed on 7 February 2017 that, on the same day, Michael Hunt, the Company's Chief Financial Officer, acquired 250,000 ordinary shares of 1p each ("Ordinary Shares") at a price of 2.64p per share.
Following this share purchase, Michael Hunt's total beneficial interest in the Company is 2,008,471 Ordinary Shares, representing 0.063 per cent of the Company's total voting rights.
ENQUIRIES:
ReNeuron | +44 (0)20 3819 8400 |
Olav Hellebø, Chief Executive Officer |
|
Michael Hunt, Chief Financial Officer |
|
Buchanan | +44 (0) 20 7466 5000 |
Mark Court, Sophie Cowles, Stephanie Watson |
|
|
|
Stifel Nicolaus Europe Limited | +44 (0) 20 7710 7600 |
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Broker) |
|
About ReNeuron
ReNeuron is a leading, clinical-stage cell therapy development company. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.
ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. The Company has therapeutic candidates in clinical development for motor disability as a result of stroke, for critical limb ischaemia and for the blindness-causing disease, retinitis pigmentosa.
ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for gene therapy treatments.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.
The notifications below, made in accordance with the requirements of the EU Market Abuse Regulation, provide further detail:
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
(Disclosure in relation to purchase of Ordinary Shares)
1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | Michael Hunt | ||||
2 | Reason for the notification | |||||
a) | Position/status | Chief Financial Officer | ||||
b) | Initial notification /Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | ReNeuron Group plc | ||||
b) | LEI | N/A | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares 0.01p
RENE - GB00B0DZML60 | ||||
b) | Nature of the transaction | Purchase of ordinary shares | ||||
c) | Price(s) and volume(s)
|
| ||||
d)
| Aggregated information
| N/A | ||||
e) | Date of the transaction | 7 February 2017 | ||||
f) | Place of the transaction | London Stock Exchange, AIM Market | ||||